Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:

NCT ID: NCT03772353 Not yet recruiting - Breast Cancer Clinical Trials

Study to Evaluate Letrozole, Pyrotinib Combined With SHR6390 in Patients With HR+/HER2+ Relapsed/Metastatic Breast Cancer

Start date: December 12, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single-center Ib / II study of triple targeted drug combination (aromatase inhibitor letrozole,novel HER2-targeted small molecule inhibitor pyrotinib and CDK4/6 inhibitor SHR6390) as a first or second line of therapy in patients with relapsed/metastatic hormone receptor positive and HER2-positive breast cancer.

NCT ID: NCT03772197 Completed - Breast Cancer Clinical Trials

Parallel Comparison of 18 Gene Classifiers and Oncotype DX:A Retrospective Study (Nanostring Platform)

Start date: June 1, 2018
Study type: Observational

A recurrence index for distant recurrence (RI-DR), an 18-gene-based clinical-genomic model, has been developed for early-stage breast cancer (EBC). In this study, we compared the prognostic performance of the RI-DR with the Oncotype DX (ODx) recurrence score (RS) for any recurrence risk type.

NCT ID: NCT03770598 Recruiting - Breast Cancer Clinical Trials

Team Based Psychosocial Care to Promote, Maintain and Restore Wellness of Breast Cancer Patients

Start date: November 28, 2018
Phase: N/A
Study type: Interventional

Researchers are trying to see if proactive identification and team based individualized care of cancer patients having emotional difficulties can improve quality of life relative to treatment as usual. Also, to see if proactive approaches to maintain wellness can prevent grief among breast cancer patients, experiencing no emotional difficulties relative to treatment as usual.

NCT ID: NCT03769415 Recruiting - Breast Cancer Clinical Trials

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA

Start date: November 6, 2018
Phase: N/A
Study type: Interventional

The HARMONY trial is an interventional trial designed to determine the impact of molecular information on clinical decision-making in metastatic breast cancer (MBC). HARMONY will enroll incident MBC patients. We will perform intrinsic subtype on the primary tumor using the PAM50 methodology in a CLIA-compliant setting and provide these data to the treating physician. In this way we will identify the congruence rates between expected and observed subtype based on clinical phenotype (e.g. luminal biology in a hormone receptor-positive tumor), survey the treating physicians regarding the impact of this biologic information on treatment decisions, and examine progression-free survival on concordant vs discordant treatment regimens. We will also examine other gene expression signatures related to tumor behavior and immune activation including signatures developed to characterize tumor-immune interaction and will perform RNA sequencing, however the results of those assays will be analyzed in an integrated fashion and will not be provided to the treating physician.

NCT ID: NCT03768258 Completed - Breast Cancer Clinical Trials

Testosterone Implants and the Incidence of Breast Cancer

Start date: March 2008
Study type: Observational

This current chart review study was designed to investigate the incidence of breast cancer in women treated with subcutaneous testosterone therapy for symptoms of hormone deficiency.

NCT ID: NCT03765983 Not yet recruiting - Breast Cancer Clinical Trials

GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

Start date: December 31, 2018
Phase: Phase 2
Study type: Interventional

This research study is studying a drug called GDC-0084 as a possible treatment for HER2-Positive Breast Cancer. The drugs involved in this study are: - GDC-0084 - Trastuzumab (Herceptin®)

NCT ID: NCT03764943 Not yet recruiting - Breast Cancer Clinical Trials

Immunonutrition and Carbohydrate Loading Strategies in Breast Reconstruction

Start date: December 2018
Phase: Phase 3
Study type: Interventional

This study is designed to test the following hypothesis: patients undergoing immediate alloplastic and autologous breast reconstruction following mastectomy that receive preoperative immunonutrition and carbohydrate loading will experience a reduction in wound complications in the 30-day postoperative period compared to a standard of care control group (retrospective chart review) of 264 (132 alloplastic + 132 autologous) consecutive breast reconstruction patients prior to 5/25/2018.

NCT ID: NCT03763851 Not yet recruiting - Breast Cancer Clinical Trials

Cannabis Oil and Radiation Therapy for the Management of Pain

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

In this innovative approach seeking effective therapeutic strategies, the investigators are proposing to test the effectiveness of medical cannabis oil as an adjunct to palliative Radiation Therapy (RT) and Best Supportive Care to alleviate cancer pain that was only partially relieved with conventional medications. Furthermore, the investigators will assess the effect of medical cannabis oil on health-related quality of life and symptoms that are frequently associated with metastatic cancers including fatigue, anxiety, depression, insomnia and decreased appetite. The safety profile of medical cannabis oil with respect to prolonged use of more than two weeks of administration, concomitant medication use and palliative RT will also be examined.

NCT ID: NCT03763825 Not yet recruiting - Breast Cancer Clinical Trials

Mini-AFTERc Intervention for Fear of Cancer Recurrence

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

People treated for breast cancer often live with an ongoing fear that the cancer will recur. This fear may develop and impact on their mental health and quality of life. The Mini-AFTERc study is a pilot trial of a brief cognitive behavioural communication intervention, designed to reduce fear of cancer recurrence (FCR) in breast cancer patients. This pilot trial aims to determine the acceptability and practicality of introducing the Mini-AFTERc intervention into everyday practice, and inform the development of a full randomised controlled trial.

NCT ID: NCT03762733 Not yet recruiting - Breast Cancer Clinical Trials

Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies

Start date: December 14, 2018
Study type: Observational

Background: A person s blood, tissue, and other samples contain DNA. Cancer is a disease of cells that are not working properly. It is caused by changes in DNA that build up. Researchers want to do future studies on DNA changes This may help them learn how to guide treatment for cancer. They need biological samples like tumors, blood, and urine for these studies. Objective: To create a place to collect and store biological samples from people with gynecologic malignancies like breast cancer. Samples from certain relatives of theirs will be collected too. Eligibility: Adults ages 18 and older who are being seen at NIH for breast cancer or other gynecologic malignancy Their biological relatives of the same age Design: Participants will answer questions about their family history. Participants will have a physical exam and medical history. This will include questions about age, ethnicity, and disease history. They will also answer questions about their medical treatments and responses. Participants will give blood and urine samples. Participants may give a tumor tissue sample. This will not be taken specifically for this study. It will be from a previous procedure or one that is already planned. Other samples may be taken only if a procedure is required for treatment. These include bone marrow, cerebrospinal fluid, and other fluids. A group of doctors and other professionals will oversee the sample storage place. The group will review all requests to be sure the use of the specimens is valid.